Advances in post mortem molecular neurochemistry and neuropathology: Examples from schizophrenia research

British Medical Bulletin

Volumn 52, Issue 3, 1996, Pages 527-538

  Harrison, Paul J ^a,b  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 4 RECEPTOR; SEROTONIN RECEPTOR;

AUTOPSY; GENE EXPRESSION; GENETIC PROCEDURES; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MENTAL DISEASE; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROCHEMISTRY; NEUROLOGY; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPSE;

EID: 0029736547     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011565     Document Type: Review

References (62)

1. Harrison PJ, Pearson RCA. Gene expression and mental disease. Psychol Med 1989; 19: 813-9
2. Harrison PJ, Pearson RCA. Principles and practice of in situ hybridization histochemistry in neuropsychiatric research. In: Roberts GW, Polak JM (eds) Molecular Neuropathology. Cambridge: Cambridge University Press, 1995; 38-60
3. Harrison PJ. In vitro brain imaging: techniques for studying and localizing the pathogenesis of psychiatric diseases. In: Kerwin RW (ed) Neuroimaging. Neurobiology and Psychiatry, vol 3. Cambridge: Cambridge University Press, 1995; 157-74
4. 2A receptor mRNAs in human hippocampus using a reverse transcriptase-polymerase chain reaction (RT-PCR) technique and their correlation with binding site densities and age. Neurosci Lett 1994; 178: 85-9
5. 2A receptor mRNA in human brain. Brain Res 1995; 676: 157-68
6. Mulcrone J, Whatley SA, Ferrier IN, Marchbanks RM. A study of altered gene expression in frontal cortex from schizophrenic patients using differential screening. Schizophr Res 1995; 14: 203-13
7. Perrett CW, Whatley SA, Ferrier IN, Marchbanks RM. Changes in relative levels of specific brain mRNA species associated with schizophrenia and depression. Mol Brain Res 1992; 12: 163-71
8. Blackstone CD, Levey AI, Martin LJ, Price DL, Huganir RL. Immunological detection of glutamate receptor subtypes in human central nervous system. Ann Neural 1992; 31: 680-3
9. Eastwood SL, Burnet PWJ, Beckwith J, Kerwin RW, Harrison PJ. AMPA glutamate receptors and their flip and flop mRNAs in human hippocampus. Neuroreport 1994; 5: 1325-8
10. 33P. J Histochem Cytochem 1993; 41: 1767-73
11. Royston MC. Neuropathology by numbers: application of image analysis techniques to quantitative neuropathology. In: Roberts GE, Polak JM (eds) Molecular Neuropathology. Cambridge: Cambridge University Press, 1995; 174-84
12. Akbarian S, Kim JJ, Potkin SG et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258-66
13. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995; 66: 309-19
14. Chen KS, Masliah E, Mallory M, Gage FH. Synaptic loss in cognitively impaired aged rats is ameliorated by chronic human nerve growth factor infusion. Neuroscience 1995; 68: 19-27
15. West MJ. Advances in the study of age-related neuron loss. Semin Neurosci 1994; 6: 403-11
16. Oorschot DE. Are you using neuronal densities, synaptic densities or neurochemical densities as your definitive data? There is a better way to go. Prog Neurobiol 1994; 44: 233-47
17. Ma SY, Collan Y, Rytt M, Rinne JO, Rinne UK. Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol 1995; 21: 10-7
18. Perry EK, Perry RH. Human brain neurochemistry: some postmortem problems. Life Sci 1983; 33: 1733-43
19. Barton AJL, Pearson RCA, Najlerahim A, Harrison PJ. Pre and post mortem influences on brain RNA. J Neurochem 1993; 61: 1-11
20. Harrison PJ, Heath PR, Eastwood SL, Burnet PWJ, McDonald B, Pearson RCA. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and a comparison with their encoded proteins. Neurosci Lett 1995; 200: 151-4
21. Kingsbury AE, Foster OJF, Nisbet AP et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol Brain Res 1995; 28: 311-8
22. Harrison PJ, Barton AJL, Procter AW, Bowen DM, Pearson RCA. The effects of Alzheimer's disease, other dementias and premortem course upon amyloid β precursor protein messenger RNAs in frontal cortex. J Neurochem 1994; 62: 635-44
23. Procter AW, Francis PT, Holmes C et al. APP isoforms show correlations with neurones but not with glia in human brain. Acta Neuropathol 1994; 88: 545-52
24. 2A receptor and response to clozapine. Lancet 1995; 346: 909
25. Nisbet AP, Foster OJF, Kingsbury A et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995; 66: 361-76
26. Vonsattel JPG, Aizawa H, Ge P et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995; 54: 42-56
27. Login GR, Dvorak AM. Application of microwave fixation techniques in pathology to neuroscience studies: a review. J Neurosci Methods 1994; 55: 173-82
28. 4 receptor with a high affinity for the antipsychotic clozapine. Nature 1991; 350: 650-4
29. van Tol HHM, Wu CM, Guan H-C et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-52
30. 4 receptors elevated in schizophrenia. Nature 1993; 365: 441-5
31. Murray AM, Hyde TM, Knable MB et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186-91
32. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 1995; 681: 109-16
33. 4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576-7
34. 3H]nemonapride. J Neurochem 1995; 64: 1413-5
35. 4 receptors by 2-fold in rats. Eur J Pharmacol 1995; 289: 67-72
36. 4 receptor variants in unrelated schizophrenic cases and controls. Am J Med Genet (Neuropsychiatr Genet) 1993; 48: 90-3
37. 4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994; 51: 912-7
38. 4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116
39. Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1995; 1215-28
40. 2 receptors. J Pharmacol Exp Ther 1993; 266: 1374-94
41. 2A receptor gene. Lancet 1995; 346: 281-2
42. 2A receptor gene. Lancet 1996; 347: 1274
43. 2A receptor mRNAs and binding site densities are differentially affected in schizophrenia. Neuropsychopharmacol 1996; In press
44. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res 1995; 33: 174-8
45. Ohm TG, Kirca M, Bohl J, Schnargl H, Gross W, Mrz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995; 66: 583-7
46. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 4725-7
47. Harrison PJ. On the neuropathology of schizophrenia: neurodevelopmental, neurodegenerative, or both? Neurodegeneration 1995; 4: 1-12
48. Weinberger DR. Schizophrenia: from neuropathology to neurodevelopment. Lancet 1995; 346: 552-7
49. Shapiro RM. Regional neuropathology of schizophrenia. Where are we? Where are we going? Schizophr Res 1993; 10: 187-239
50. Masliah E, Terry RD, Alford M, DeTeresa R. Quantitative immunohistochemistry of synaptophysin in human neocortex: an alternative method to estimate density of presynaptic terminals in paraffin sections. J Histochem Cytochem 1990; 38: 837-44
51. Masliah E, Terry RD. The role of synaptic proteins in the pathogenesis of disorders of the nervous system. Brain Pathol 1993; 3: 77-86
52. Eastwood SL, Burnet PWJ, McDonald B, Clinton J, Harrison PJ. Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study. Neuroscience 1994; 59: 881-92
53. Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience 1995; 69: 339-43
54. Arnold SE, Franz BR, Gur RC et al. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 152: 738-48
55. Goldsmith SK, Joyce JN. Alterations in hippocampal mossy fiber pathway in schizophrenia and Alzheimer's disease. Biol Psychiatry 1995; 37: 122-6
56. Barbeau D, Liang JJ, Robitaille Y, Quirion R, Srivastava LK. Decreased expression of the embryonic form of the nerve cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci USA 1995; 92: 2785-90
57. Harrison PJ, Eastwood SL, Esiri MM, Zaidel DW. Cytoarchitectural hippocampal asymmetries in schizophrenia. Schizopbr Res 1996; 18: 180
58. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry 1993; 34: 529-35
59. Jorgensen OS. Neural cell adhesion molecule (NCAM) as a quantitative marker in synaptic remodelling. Neurochem Res 1995; 20: 533-47
60. Takahashi S, Yamamoto H, Matsuda Z et al. Identification of two highly homologous presynaptic proteins distinctly located at the dendritic and somatic synapses. FEBS Lett 1995; 368: 455-60
61. Benes FM. Post-mortem structural analyses of schizophrenic brain: study designs and the interpretation of data. Psychiatr Dev 1988; 3: 213-26
62. Kerwin RW. Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. Psychol Med 1993; 23: 547-51